New Delhi: The Ayush Ministry has collaborated with the School of Hygiene and Tropical Medical London England (LSHTM) to conduct a study of Ashwagandha to promote recovery from Covid-19.
The All India Institute of Ayurveda (AIIA), an autonomous body under the Ayush Ministry, and LSHTM recently signed a memorandum of understanding to conduct Ashwagandha’s clinical trials at 2,000 in three UK – Leicingham, and London (Southall and London Wembley cities), said Ministry in a statement.
Ashwagandha (with Somnifera), commonly known as ‘Indian winter cherries’, is a traditional herb that increases energy, reduces stress and makes the immune system stronger.
This is a nutritional supplement that is easily accessible, over-the-counter in the UK and has a proven security profile, he said.
The success of settlement of the trial can be a major breakthrough and provide scientific validity to the traditional Indian drug system.
Although there are several research on Ashwagandha to understand the benefits in various diseases, this is the first time the Ayush Ministry collaborates with foreign institutions to investigate its efficacy in Covid-19 patients, he added.
According to Director of AIIA, Dr.
Tanuja Manoj Nesari, who is also a joint investigation in the project together with Dr.
RajoPalan, international projects, participants have been randomly selected.
Dr.
Sanjay Kinra from LSHTM is the main researcher of this study.
“For three months, a group of 1,000 participants will be given ashwagandha tablet (AG) while the second group of 1,000 participants will be assigned placebo, which cannot be distinguished from AG in appearance and taste.
Both patients and doctors will not realize the Group’s maintenance in the test Try a double blind, “said Dr.
Nesari in the statement.
The participants must take a 500 mg tablet twice a day.
The monthly follow-up of the quality of life reported itself, decreasing value in daily living activities, symptoms of mental and physical health, the use of supplements and side effects will be carried out.
It took more than 100 meetings that stretched around 16 months through diplomatic channels and regulations for the signing of the MoU, said Dr.
Nesari.
He added that this research was approved by drugs and the Health Product Regulatory Agency (MHRA) and certified by WHO-GMP.
It is being carried out and monitored in accordance with the GCP guidelines (good clinical practice) that internationally recognized, he added.
Recently, a number of randomized placebo-controlled trials from Ashwagandha in humans in India have demonstrated its efficacy in reducing anxiety and stress, increasing muscle strength and reducing symptoms of fatigue in chronic conditions.
It has also been indicated to treat non-restorative sleep, characteristic of chronic fatigue, where the trial is currently underway, the statement said.
Combined with substantial literature on the pharmacological effects and immunomature in vitro and in animals, this study shows Ashwagandha as a potential prospective therapy to reduce the long-term symptoms of Covid-19, he added.
After the success of the trial, Ashwagandha will be a medicinal treatment that is proven to prevent infection and be recognized by the scientific community throughout the world.
Despite the development of successful vaccines, Covid-19 continues to pose a substantial threat to health in the UK and globally.
More than 15 percent of adults in the UK, where clinical trials in Ashwagandha will occur, and more than 10 percent globally have been infected with the SARS-COV-2 virus.